Pexidartinib: First Approval

A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors

(2019) Jih-Hsiang Lee et al.   INVESTIGATIONAL NEW DRUGS

MEDIPLEX: A phase 1 study of durvalumab (D) combined with pexidartinib (P) in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC).

(2019) Philippe Alexandre Cassier et al.   JOURNAL OF CLINICAL ONCOLOGY

Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial

(2019) William D Tap et al.   LANCET

A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal Tumor

(2019) Evan Rosenbaum et al.   ONCOLOGIST

1696PPexidartinib (Pex) for locally advanced tenosynovial giant cell tumour (TGCT): Characterization of hepatic adverse reactions (ARs)

(2019) S Bauer et al.   ANNALS OF ONCOLOGY

Phase 1b/2 study of pexidartinib (PEX) in combination with radiation therapy (XRT) and temozolomide (TMZ) in newly diagnosed glioblastoma.

(2018) Howard Colman et al.   JOURNAL OF CLINICAL ONCOLOGY

First prospective observational study in diffuse-type tenosynovial giant cell tumors.

(2018) Monique Mastboom et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of PLX9486 alone and in combination (combo) with the KIT inhibitors pexidartinib (pexi) or sunitinib (su) in patients (Pts) with advanced solid tumors and gastrointestinal stromal tumor (GIST).

(2018) Andrew J. Wagner et al.   JOURNAL OF CLINICAL ONCOLOGY

Modulating the Tumor Microenvironment via Oncolytic Viruses and CSF-1R Inhibition Synergistically Enhances Anti-PD-1 Immunotherapy

(2018) Gang Shi et al.   MOLECULAR THERAPY

Colony-Stimulating Factor 1 Receptor Blockade Inhibits Tumor Growth by Altering the Polarization of Tumor-Associated Macrophages in Hepatocellular Carcinoma

(2017) Jian-Yang Ao et al.   MOLECULAR CANCER THERAPEUTICS

Inhibition of colony stimulating factor-1 receptor abrogates microenvironment-mediated therapeutic resistance in gliomas

(2017) D Yan et al.   ONCOGENE

Patient-reported Symptoms of Tenosynovial Giant Cell Tumors

(2016) Heather L. Gelhorn et al.   CLINICAL THERAPEUTICS

Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study

(2015) Nicholas Butowski et al.   NEURO-ONCOLOGY

Colony stimulating factor 1 receptor inhibition delays recurrence of glioblastoma after radiation by altering myeloid cell recruitment and polarization

(2015) Jason H. Stafford et al.   NEURO-ONCOLOGY

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor

(2015) William D. Tap et al.   NEW ENGLAND JOURNAL OF MEDICINE

Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397

(2015) C. C. Smith et al.   Cancer Discovery

Sustained Inhibition of Receptor Tyrosine Kinases and Macrophage Depletion by PLX3397 and Rapamycin as a Potential New Approach for the Treatment of MPNSTs

(2014) P. P. Patwardhan et al.   CLINICAL CANCER RESEARCH

Inhibition of CSF-1 Receptor Improves the Antitumor Efficacy of Adoptive Cell Transfer Immunotherapy

(2013) S. Mok et al.   CANCER RESEARCH

Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy

(2011) David G. DeNardo et al.   Cancer Discovery